In DLBCL, a comparison between differentially expressed genes (DEGs) of tumor cells and non-cancer samples, which were extracted from Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) in the drug-gene interaction database, revealed that ANXA5 is a target for Daunorubicin, a drug similar to Doxorubicin [85]. The gene discussed is ANXA5; the disease is diffuse large B-cell lymphoma.